Royalty Pharma (STU:RPD) Non Operating Income : €339 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. Royalty Pharma's Non Operating Income for the three months ended in Mar. 2024 was €98 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was €339 Mil.

Royalty Pharma Non Operating Income Historical Data

The historical data trend for Royalty Pharma's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Non Operating Income Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Non Operating Income

Get a 7-Day Free Trial

76.04

139.89

-68.06

-550.54

296.04

Royalty Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Non Operating Income	Get a 7-Day Free Trial															56.38	114.26	-6.34	133.37	97.81

Royalty Pharma Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €339 Mil.

Royalty Pharma Non Operating Income Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma (STU:RPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Non Operating Income

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico

Address

110 East 59th Street, FL 33, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.